Cat. No. 5576
Chemical Name: N-[2,3-Dihydro-1,3-dimethyl-2-oxo-6
Biological ActivityPotent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4. Disrupts BRPF1 binding to histone H3.3. Cell permeable.
Licensing InformationThis probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the PFI 4 probe summary on the SGC website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Demont et al (2014) 1,3-Dimethyl Benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med.Chem.Lett. 5 1190. PMID: 25408830.
If you know of a relevant reference for PFI 4 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PFI 4 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PFI 4, supplier, PFI4, potent, selective, BRPF1, bromodomains, epigenetics, inhibitors, inhibits, sgc, Tocris Bioscience, Bromodomain Inhibitor products
Find multiple products by catalog number
New Products in this Area
BET bromodomain inhibitor; orally bioavailableH3K4(Me2) (1-20)
Histone H3 peptideTC AC 28
High affinity BET bromodomain ligandTP 472N
Negative control for TP 472 (Cat. No. 6000).
Tocris has a collaboration with the Structural Genomics Consortium (SGC) to provide the latest high quality epigenetics probes.